COMMUNIQUÉS West-GlobeNewswire

New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
25/04/2025
Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of the influenza virus, from an infected person to household members by 32% 1 CENTERSTONE is the first [...]
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
25/04/2025
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance [...]
Champions for Change Celebrated at 2025 Helen Keller Achievement Awards
25/04/2025
Author Andrew Leland Breaks Down Misconceptions of People with Disabilities; Business Leader Thomas Wlodkowski Recognized for Bolstering Access to Media; Mattel Lauded for Blind Barbie’s Global Impact on Positive [...]
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
25/04/2025
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
25/04/2025
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
24/04/2025
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its [...]
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
24/04/2025
VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
24/04/2025
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results [...]
Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025
24/04/2025
LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
24/04/2025
Exosome-Based ExoPTEN Targets Three High-Value Nerve Injury Indications TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “ [...]
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
24/04/2025
Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a first installment of € [...]
GENFIT : Résultats financiers annuels 2024 et point sur les activités de la Société
24/04/2025
Trésorerie et équivalents de trésorerie s’élevant à 81,8 millions d’euros au 31 décembre 2024. En outre, conclusion, en début d’année (i) d’un accord de royalty financing non dilutif d'un montant maximum de 185 millions [...]
Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025
24/04/2025
FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close [...]
Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025
24/04/2025
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, [...]
Treace to Report First Quarter 2025 Financial Results on May 8, 2025
24/04/2025
PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
24/04/2025
GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
24/04/2025
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances
24/04/2025
New study establishes CHIPS as a foundation for engineered, vascularized, insulin-producing tissue systems WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic [...]
Seer to Report First Quarter 2025 Financial Results on May 13, 2025
24/04/2025
REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial [...]

Pages